Emtricitabine/rilpivirine/tenofovir disoproxil (as fumarate) (Eviplera®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014001440
English
Authors' recommendations:
Emtricitabine/rilpivirine/tenofovir disoproxil (Eviplera®) is recommended as an option for use within NHS Wales for antiretroviral treatmentexperienced adults infected with human immunodeficiency virus type 1(HIV-1) without known mutations associated with resistance to the nonnucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ≤ 100,000 HIV-1 RNA copies/ml. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera®.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2374
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Adenine
- Deoxycytidine
- Nitriles
- Pyrimidines
- Organophosphonates
- HIV
- HIV Infections
- Drug Therapy, Combination
- Rilpivirine
- Emtricitabine, Rilpivirine, Tenofovir Drug Combination
- Reverse Transcriptase Inhibitors
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.